Introduction
th generation HIV assays, generally known as combo assays, entered practice in 2010 after FDA approval. Main difference from its former version is the test now can detect p24 antigen which permits earlier detection of infection. Various companies introduced their combo assays for their immunoassay systems: Siemens HIV antigen/antibody (Ag/Ab) Combo Assay for Siemens AD-VIA Centaur® XP (ADVIA); and Roche Diagnostics HIV combi assay for Roche Modular Analytics E170 (Roche). ADVIA uses antigen-bridging, magnetic-microparticle chemiluminometric immunoassay for: HIV-1 groups M and O antibodies; and HIV-2 antibodies; and HIV-1 p24 antigen. Roche uses electrochemiluminescence immunoassay for same antibodies and antigen. The results from both systems are expressed in index values and an index value higher than 1.0 is commonly considered initial positive. This initial positive sample is repeatedly tested in duplicate and then if either or both replicates a positive result, the sample then considered repeatedly positive. Afterwards, confirmation of HIV status is made by Western Blot (WB) analysis with or without the need of RNA Nucleic Acid Amplification test depending on the WB result.
Discussion
Very low false-positive and false-negative rates for ADVIA were recently reported (Sensitivity: 100%; 95% confidence interval: 99.39-100.00%. Specificity: 99.74%; 95% confidence interval: 99.60-99.84%) [1] . On the other hand, a study performed in UK with a 4 th generation HIV POCT kit showed high false positive results for p24 portion of the kit and authors suggested using a 3 rd generation HIV kit for outreach testing and with a backup of 4 th generation laboratory-based EIA for highrisk individuals [2] . Hence the only difference between 3 rd and 4 th generation HIV assays is 4 th generation having additional antibodies for p24, the probability of crossreaction to self or external source antigens, antibodies or peptides is higher. A retrospective cohort evaluation of patient records in a physical medicine and rehabilitation training and research hospital from September 1, 2011 to December 12, 2011 gave out 4 samples with repeatedly positive EIA results with ADVIA in 831 samples. 3 of the patients had index values between 1.0 and 2.0 and one patient had 11.5. These 4 samples had additional testing with Roche which showed non-reactive results. The sample with index value of 11.5 also underwent WB analysis. The result was negative for HIV infection. The 4 false positive results from ADVIA indicate a lower specificity compared to Roche. Key points causing this are thought to be differences in detection systems and discrete antibodies, antigens and peptides used. The above situation suggests, although both assays are 4 th generation, ADVIA has a higher false positive rate and results must be confirmed with another test before reporting as positive for HIV infection, especially if the patient has a low risk for HIV infection.
Conclusion
Reporting HIV positive results gives responsibility to the laboratory. False positive results may cause problems. Clinicians who are not familiar with similar cases may blame laboratory for false positive results. Laboratory directors should regularly give feed-back to clinicians about tests run in the laboratory and their performance data.
